🇺🇸 Actrapid (human insulin) in United States
57 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 21 April 2025 – 21 April 2026
- Total reports: 57
Most-reported reactions
- Drug Interaction — 10 reports (17.54%)
- Hypoglycaemia — 8 reports (14.04%)
- Blood Creatinine Increased — 6 reports (10.53%)
- Bradycardia — 6 reports (10.53%)
- Coma — 6 reports (10.53%)
- Condition Aggravated — 5 reports (8.77%)
- Atrial Fibrillation — 4 reports (7.02%)
- Blood Glucose Increased — 4 reports (7.02%)
- C-Reactive Protein Increased — 4 reports (7.02%)
- General Physical Health Deterioration — 4 reports (7.02%)
Other Diabetes approved in United States
Frequently asked questions
Is Actrapid (human insulin) approved in United States?
Actrapid (human insulin) does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for Actrapid (human insulin) in United States?
University of Aarhus is the originator. The local marketing authorisation holder may differ — check the official source linked above.